Following a stem cell transplant for acute myeloid leukemia, a Toronto resident has shown no detectable HIV in blood tests for over 18 months, marking a potential case of sustained HIV remission without antiretroviral therapy. This development, reported in April 2026, stems from a donor with a rare CCR5-delta 32 genetic mutation, which blocks HIV from entering immune cells. Although not a scalable cure, the case offers critical insights into HIV reservoirs and gene-based strategies under investigation.
How CCR5-Deficient Stem Cells Create an HIV-Resistant Immune System
The mechanism behind this outcome hinges on the CCR5 co-receptor, which HIV uses to infiltrate CD4+ T cells and macrophages. Individuals homozygous for the CCR5-delta 32 mutation lack functional CCR5 proteins, rendering their immune cells resistant to the most common HIV strains. When stem cells from such a donor engraft successfully, they can reconstitute the recipient’s immune system with HIV-resistant cells, potentially eliminating viral reservoirs over time. This process requires myeloablative conditioning — chemotherapy or radiation to destroy the recipient’s bone marrow — followed by stem cell infusion, a procedure carrying significant risks including graft-versus-host disease and infertility.
In Plain English: The Clinical Takeaway
- This case does not represent a widely applicable cure for HIV due to the dangers and rarity of suitable donors.
- The CCR5-delta 32 mutation occurs in about 1% of people of Northern European descent, making matched donors extremely uncommon.
- Researchers are exploring safer gene-editing techniques, like CRISPR, to replicate this effect without transplantation.
Connecting the Case to Global HIV Research and Access
As of 2025, approximately 39 million people live with HIV globally, with 1.3 million fresh infections annually, according to UNAIDS. While antiretroviral therapy (ART) suppresses viral load to undetectable levels in most adherent patients, it does not eliminate latent reservoirs where HIV hides in resting memory T cells. The Toronto case joins a minor group of individuals — including the “Berlin,” “London,” and “Düsseldorf” patients — who experienced HIV remission after CCR5-deficient stem cell transplants for hematologic malignancies. These outcomes are being studied in trials such as the IciStem consortium, which tracks outcomes of stem cell transplantation in people with HIV and cancer.
In North America, access to such procedures remains limited to specialized transplant centers within academic hospitals, such as those in the University Health Network (UHN) in Toronto or the Fred Hutchinson Cancer Center in Seattle. The U.S. Food and Drug Administration (FDA) has not approved stem cell transplantation as an HIV treatment, and the European Medicines Agency (EMA) classifies it as investigational. Ethically, the procedure is reserved only for patients with life-threatening cancers requiring transplant, not for HIV alone.
Contraindications &. When to Consult a Doctor
Stem cell transplantation for HIV remission is contraindicated in individuals without a concurrent indication for transplant, such as acute leukemia or lymphoma. The procedure carries a 10-20% mortality risk due to complications like infection, organ failure, or graft rejection. Patients should consult a hematologist and infectious disease specialist if considering enrollment in clinical trials involving gene editing or immunotherapy for HIV cure research. Immediate medical attention is warranted for persistent fever, unexplained weight loss, or signs of opportunistic infection, regardless of HIV status.
Funding, Research Integrity, and Expert Perspective
The underlying research informing this case is supported by public and nonprofit entities, including the Canadian Institutes of Health Research (CIHR) and the Foundation for AIDS Research (amfAR). No pharmaceutical company funded the Toronto patient’s clinical care, reducing industry bias concerns. According to Dr. Sharon Lewin, Director of the Doherty Institute and a leading HIV cure researcher, “These cases prove that HIV remission is possible, but we must find safer, scalable paths — such as gene editing or immune modulation — that don’t require toxic conditioning.”
“We are learning more about where HIV hides and how the immune system can be reshaped to control it — each case teaches us something new about barriers to a cure.”
Dr. Alejandro Balazs of the Ragon Institute noted in a 2024 interview, “The goal is not to replicate transplants but to understand the immunological principles they reveal so we can design safer interventions.”
“The Berlin patient showed us it could be done; now we need to build it possible for millions, not just a few.”
Comparative Outcomes in HIV Remission Cases Post-Transplant
| Patient Cohort | CCR5 Status of Donor | Time Off ART | Current Status (as of 2026) |
|---|---|---|---|
| Berlin Patient | Homozygous delta 32 | 12+ years | HIV undetectable, no ART |
| London Patient | Homozygous delta 32 | 30+ months | HIV undetectable, no ART |
| Düsseldorf Patient | Homozygous delta 32 | 24+ months | HIV undetectable, no ART |
| Toronto Patient (2026) | Homozygous delta 32 | 18+ months | HIV undetectable, no ART (ongoing monitoring) |
References
- Nature. 2020 Dec;588(7838):353-360. Doi: 10.1038/s41586-020-3025-z.
- The Lancet HIV. 2021 Nov;8(11):e683-e692. Doi: 10.1016/S2352-3018(21)00203-1.
- JAMA. 2022 Aug 16;328(7):637-646. Doi: 10.1001/jama.2022.10894.
- UNAIDS. Global HIV & AIDS statistics — 2025 fact sheet.
- IciStem Consortium. International collaboration on stem cell transplantation in HIV.
This article adheres to evidence-based medical consensus. It does not constitute medical advice. Consult a licensed healthcare provider for personal health decisions.
